Skip to main content
Funded Studies

Richard Gordon, PhD, DABT

Professor of Neuroscience at Queensland University of Technology

Location: Brisbane QLD Australia

Richard Gordon leads the translational neuroscience program at The Queensland University of Technology Centre for Microbiome Research (CMR) within the Translational Research Institute (TRI) in Brisbane, Australia. His research program aims to understand how inflammatory pathways become activated and intestinal microbiota disrupted in Parkinson’s disease (PD), and how this contributes to disease progression. These findings are used to develop biomarkers for early diagnosis of PD as well as new treatment strategies aimed at slowing disease progression in people with PD. Dr. Gordon’s research has contributed to groundbreaking advances in this field, including most recently, the discovery of inflammasome activation as a driver of alpha-synuclein pathology and PD disease progression. Dr. Gordon is a certified toxicologist with the American Board of Toxicology (ABT) and serves on the Australian Therapeutics Goods Administration (TGA) Advisory Committee on Chemicals Scheduling. He is also a science ambassador for the World Parkinson Coalition (WPC).


Associated Grants

  • Evaluation of the Inflammation-blocking Drug Tolebrutinib as a Novel Disease-modifying Therapeutic for Parkinson's Disease

    2023


  • Validation of RRx-001 as a Novel Disease-modifying Therapeutic for Parkinson's Disease

    2022


  • Exploring How a Chemical Produced by Intestinal Microbes Contributes to the Pathology and Progression of Parkinson's Disease

    2021


  • Development of an Anti-inflammatory Drug for the Treatment of Parkinson’s Disease

    2021


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.